Search results
Medicare Advantage Star Ratings proposal targets top performers
Modern Healthcare· 6 days agoAt issue is what's known as the "hold harmless" policy. Medicare Advantage contracts that earn at least 4 out of 5 stars can choose to disregard two highly weighted “quality improvement” elements ...
Fight Denied Medicare Claims: Find the Best Appeal Path
TheStreet.com· 3 days agoDiscover the right appeal path to combat denied Medicare claims. Jae Oh explains the best ways to get coverage approved. Approval to receive coverage for treatment under one's Medicare package ...
Gateway - Quartz
Quartz· 5 days agoCenters for Medicare and Medicaid Services (CMS) announced on Thursday. “CMS has issued guidance to Medicare Part D plans stating that ...
Final Section 1557 Rules: Highlights for Health Plan Sponsors | JD Supra
JD Supra· 4 days agoThe U.S. Department of Health and Human Services (HHS) has issued final regulations on the nondiscrimination rules set forth in Section 1557 of the Affordable Care Act. The new rules apply to ...
Letter: We need alternatives to opioids
Bangor Daily News· 3 days agoAs a retired millworker, I have witnessed the devastating impact of the opioid crisis on mill towns throughout Maine and communities around the entire...
Gateway - Quartz
Quartz· 5 days agoAfter dominating the market for weight loss drugs, Ozempic maker Novo Nordisk has set its sights on tackling treatments for heart disease next. Cardior, a Germany-based drug maker, develops ...
JD Supra: The ACA 1557 Final Regulations: Plans and Plan Sponsors as Covered Entities
JD Supra· 3 days agoIn a recent On the Subject (available here), we reported on the impact of the final rule (final rule) interpreting Section 1557 of the Affordable Care Act (ACA) on self-funded group health plans ...
Gateway - Quartz
Quartz· 6 days agoNovo Nordisk, the maker of the mega-popular diabetes and weight loss medications Ozempic and Wegovy, is set to report its first quarter earnings on May 2. The Danish pharma giant is one-half ...
US Drug Negotiations Plan Shifts Focus for Rare Disease Programs
Bloomberg Law· 6 days agoThe rare disease community is pushing for changes in the Inflation Reduction Act’s drug price-setting scheme as it leads more drugmakers and investors to reconsider development of drugs to treat ...
